Pages that link to "Q34482767"

The following pages link to A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. (Q34482767):

Displaying 45 items.

• Antiviral drugs for viruses other than human immunodeficiency virus (Q24635330) (← links)
• Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines (Q27000080) (← links)
• Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments (Q27008984) (← links)
• Viral hepatitis in Hawai'i--differing perspectives (Q28729042) (← links)
• Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues (Q33492413) (← links)
• Antiviral therapy and resistance with hepatitis B virus infection (Q33787531) (← links)
• Novel approaches towards conquering hepatitis B virus infection (Q33787687) (← links)
• Chronic hepatitis B. (Q34002160) (← links)
• Safety and efficacy of oral HD-03/ES given for six months in patients with chronic hepatitis B virus infection (Q34382110) (← links)
• Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? (Q35033732) (← links)
• Management of hepatitis B in developing countries (Q35635637) (← links)
• Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B. (Q35844432) (← links)
• Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections (Q36185647) (← links)
• Chronic hepatitis B--who should be treated? (Q36568440) (← links)
• Targets of emerging therapies for viral hepatitis B and C. (Q36653655) (← links)
• Management of hepatitis B: summary of a clinical research workshop (Q36773747) (← links)
• Management of chronic hepatitis B: consensus guidelines (Q36849343) (← links)
• Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management (Q36863124) (← links)
• Molecular testing in the diagnosis and management of chronic hepatitis B (Q36881140) (← links)
• Novel therapies in hepatitis B and C. (Q37140034) (← links)
• Management of hepatic complications in HIV-infected persons (Q37151303) (← links)
• Management of hepatitis B virus co-infection on and off antiretroviral therapy (Q37176668) (← links)
• Treatment of chronic hepatitis B infection: an update of Swedish recommendations (Q37201573) (← links)
• Drug targets in hepatitis B virus infection. (Q37411584) (← links)
• Benefits and risks of nucleoside analog therapy for hepatitis B. (Q37462520) (← links)
• Then and now: the progress in hepatitis B treatment over the past 20 years (Q37581346) (← links)
• Hepatitis B therapies and antiviral resistance detection and management (Q37636111) (← links)
• A review of oral antiretroviral therapy for the treatment of chronic hepatitis B. (Q37768591) (← links)
• Management of HIV and hepatitis virus coinfection (Q37772508) (← links)
• Molecular methods in the diagnosis and management of chronic hepatitis B (Q37801940) (← links)
• Review article: current antiviral therapy of chronic hepatitis B. (Q37943006) (← links)
• Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials (Q38809405) (← links)
• Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. (Q42124703) (← links)
• Amino acid esters substituted phosphorylated emtricitabine and didanosine derivatives as antiviral and anticancer agents (Q42220956) (← links)
• Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. (Q42687039) (← links)
• The "return" of hepatitis B. (Q42726123) (← links)
• Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation (Q44966178) (← links)
• Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection (Q45385777) (← links)
• Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection (Q45388069) (← links)
• Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. (Q46002956) (← links)
• Drugs treatment of hepatitis B (Q46172269) (← links)
• Hepatitis B in patients with HIV infection (Q46188049) (← links)
• Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B (Q46188062) (← links)
• Clevudine: a promising therapy for the treatment of chronic hepatitis B (Q57211211) (← links)
• Emtricitabine for adults with lamivudine‐resistant chronic hepatitis B virus infection (Q94328073) (← links)